An expert clinical advisory panel convened by mental health company Spring Health has released what it calls the first open source evaluation for validating AI in mental health. The benchmark is aimed ...

Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...

Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, but sales were ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Discover Regeneron’s Q3 2025 earnings: strong Dupixent, Libtayo & EYLEA HD growth, R&D updates, plus key manufacturing and regulatory challenges.

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales(recorded by Sanofi) increased 27% ...

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 ...

No Notifications Policy “I don’t have notifications,” Dimon told CNN’s Erin Burnett. “If you sent me a text during the day, I probably do not read it.” The only people ...

Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma ...